Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

ctions and infestations, which were observed in 72% of patients on everolimus and 67% of patients on placebo(1).

EXIST-1 enrolled 117 patients in 10 countries, including the US, Poland, Russia, Germany, Belgium, Canada, Australia, Italy, the Netherlands and the UK(1,10).

About the Phase II studyIn this prospective, open-label, single-arm study, 28 patients aged three years and above (median age=11, range 3-34) with evidence of SEGA growth received a median daily dose of 5.29 mg/m2. The median treatment duration was 34.2 months (range 4.7-47.1 months). Of the 28 patients in the initial study, 27 were enrolled in the extension phase and 25 were still receiving everolimus at the extension phase cut-off date (December 31, 2010). No patients discontinued due to disease progression, adverse events or study drug use(5).

During this extension phase, reduction in SEGA volume was maintained over time and no patients required surgery or other therapy for SEGA or hydrocephalus. In the study, 78% of patients (7 of 9) who took everolimus for at least three years and 79% of patients (19 of 24) who took everolimus for at least two years experienced a reduction of 30% or greater in the size of their largest SEGA relative to baseline. Additionally, 56% of patients (5 of 9) who took everolimus for at least three years and 50% of patients (12 of 24) who took everolimus for at least two years experienced a reduction of 50% or greater in the size of their largest SEGA relative to baseline(5). These findings were consistent with those previously recorded at six months relative to baseline(2,5).

The most common AEs (all grades with an incidence of at least 20%) included: stomatitis or mouth sores (86%), upper respiratory tract infection (86%), sinusitis (47%), middle ear infection (36%), diarrhea (32%), fever (32%), cellulitis or acute infection of the deep tissues of skin or muscle (29%), convulsion (29%), gastroenteritis or inflammation of the gastrointest
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... YORK and LONDON , ... of market intelligence, MarketResearch.com is pleased to announce the ... and Consultancy focusing on the active pharmaceutical ingredient (API) ... visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In IQ4I,s ... – Forecast to 2020 , IQ4I ...
(Date:11/26/2014)... Reinforcing its commitment to enabling confident diagnosis ... PHG AEX: PHIA) today announced 510(k) clearance from ... IQon Spectral CT , presenting an entirely new ... a new dimension to Computed Tomography (CT) imaging, delivering ... based on their material content within a single scan. ...
(Date:11/26/2014)... 25, 2014  Unilife Corporation (NASDAQ: UNIS, ASX: UNS), ... systems, today announced that its Chairman and CEO, ... Piper Jaffray 26th Annual Healthcare Conference at the New ... December 2, 2014. The conference presentation ... listen only Webcast. To listen, please go to: ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3Philips receives FDA 510(k) clearance for IQon Spectral CT 2Philips receives FDA 510(k) clearance for IQon Spectral CT 3Unilife to Present at the Piper Jaffray 26th Annual Healthcare Conference on December 2nd 2
... 27, 2011   FHSSA counts its partnership initiative ... known as the Foundation for Hospices in Sub-Saharan ... between US hospice programs and organizations providing care ... assistance, support and friendship.  They are working collaboratively ...
... /PRNewswire-Asia/ -- On October 18, 2011, the "TICH- BIOTRONIC ... by TEDA International Cardiovascular Hospital (hereinafter referred to as ... Co. KG of Germany. This center is the first ... for the online monitoring of the conditions of patients ...
Cached Medicine Technology:FHSSA Launches New Campaign to Partner US Hospices with Programs in Sub-Saharan Africa 2"TICH- BIOTRONIC Pacemaker Wireless Monitoring Services Centre" Founded 2"TICH- BIOTRONIC Pacemaker Wireless Monitoring Services Centre" Founded 3
(Date:11/28/2014)... Dr. Andrew Campbell, one of the ... expansion of Quintessa Aesthetic Center into a third location ... W307 N1497 Golf Road in Suite 200 and will ... the new Delafield location will offer a variety of ... Botox, filler injectables , micro laser peels, chemical ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Dr. Paul Vitenas, one ... hold a Glitter & Glow Holiday Event for those in the ... offered at his practice. Glitter & Glow will take place on ... Vitenas’ new location in the heart of Houston at 4208 Richmond ... holidays and hope that you will come and celebrate the season ...
(Date:11/28/2014)... Written and narrated by award winning author Dr. ... “The Happiest Man In the World: Life Lessons From a ... why Project C.U.R.E. came to be. , Raised in the ... Reverend Richard W. Jackson, Dr. Jackson exceeded his goal of ... that he wasn’t happy. Prompted by this realization, James and ...
(Date:11/28/2014)... Alex Kramer HealthDay Reporter ... involved in the kitchen, through cooking classes or at home, ... to a recent review. Cooking programs and classes for ... according to the new research. And, although the review didn,t ... that such programs might help children develop long-lasting healthy habits. ...
(Date:11/28/2014)... 2014 An inventor and dental assistant from ... patient’s filling and it was almost impossible to reach. "This ... she said. , The patent-pending Access Light allows for easier ... areas of the mouth, as well as avoids harm to ... Easy to use and clean, it also helps prevent cross-contamination. ...
Breaking Medicine News(10 mins):Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3Health News:Thanksgiving Weekend Audiobook Treat! “The Happiest Man In the World: Life Lessons From a Cultural Economist” by Dr. James W. Jackson 2Health News:Want Kids to Eat Better? Get Them Cooking 2Health News:Want Kids to Eat Better? Get Them Cooking 3
... case of the disease fears of the deadly SARS virus ... cleared a woman suspected of being India's first SARS case. ... a hospital after he arrived from Australia via Singapore. He ... those of the deadly SARS virus.// ,Airport authorities in ...
... at St Mary's Hospital, Manchester, UK, has shown that family history ... with breast cancer. A survey of a group of 99 women ... a third of them had a strong history of either breast ... of cancer, 44 per cent were found to carry// mutations in ...
... Pennsylvania School of Medicine in,Philadelphia, USA, has shown that people ... ability much similar to those who go without sleep for ... the March issue of the,journal Sleep involved 48 participants divided ... for two weeks, the second group slept six hours a ...
... new study by researchers at the Institute of Neurology, ... migraine attack. The researchers who,studied 97 people with migraine ... into the condition and also help manage it better.// ... hand-held electronic diary to record,symptoms of the attack on ...
... help improve patient safety by reducing medication errors. Medication errors ... 7,000 deaths. These errors have been attributed to problems of ... or too many new drugs for doctors to remember as ... between 45,000 and 98,000 death due to medical mistakes. The ...
... called juvenile macular degeneration, is an inherited disease which ... from a defect in the ABCR gene, which is ... a vision byproduct, from retinal rods and cones. Rods ... layer of cells near the retina. The accumulation of ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: